TP53 and hematopoietic and lymphoid system neoplasm: Pharmacological p53 inhibition has been proposed to attenuate acute toxicity and decrease the risk of radiation-related blood cancer development.46 However, p53 is ubiquitously expressed which may limit therapeutic approaches.